Track how companies discuss tariffs and trade policies in their earnings calls, and understand their impact across different industries and regions.
We expect the implementation of tariffs or potential retaliatory cash as their effects remain unknown.
our team has done a nice job running the DBS playbook to offset cost pressures from tariffs
we've not quantified that. I know it is a significant step up in the tariff rates, I think, going to effect next month.
we realized quarter to date tariff impacts of approximately $100 million.
the overall market environment remains essentially unsettled, and there is still uncertainty persisting regarding future administration policies affecting the biopharmaceutical industry.
The second quarter net impact of $1.1 billion was slightly lower than we had expected due to the timing of certain indirect tariff costs.
We want to be balanced in our guidance for the second half given the uncertainty that we've seen, you know, around, you know, what's gonna happen with tariffs.
we do not currently anticipate a material impact on our business from recently introduced or discussed tariffs.
Tariffs also remain a variable in this outlook.
the direct impact of the current tariffs is immaterial to NXP's financials.